Da Rentang announced that Xinxin Pharmaceutical Factory, a branch of the company, recently received the “Drug Registration Certificate” for saxagliptin metformin sustained-release tablets approved and issued by the State Drug Administration. The drug is suitable for adults with type 2 diabetes. The total domestic sales volume in 2025 is about 480 million yuan, an increase of about 33% over the previous year. Once approved, it is considered to have passed the consistency evaluation and will not have a significant impact on the company's recent performance. Drugs are approved for production and sale or are affected by uncertainties, and the future scale of production and sales is uncertain.

Da Rentang announced that Xinxin Pharmaceutical Factory, a branch of the company, recently received the “Drug Registration Certificate” for saxagliptin metformin sustained-release tablets approved and issued by the State Drug Administration. The drug is suitable for adults with type 2 diabetes. The total domestic sales volume in 2025 is about 480 million yuan, an increase of about 33% over the previous year. Once approved, it is considered to have passed the consistency evaluation and will not have a significant impact on the company's recent performance. Drugs are approved for production and sale or are affected by uncertainties, and the future scale of production and sales is uncertain.